Wells Fargo
BPMC

Wells Fargo’s Blueprint Medicines BPMC Stock Holding History

Wells Fargo’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,338
Closed -$4.53M – 7102
2025
Q2 		$4.53M Buy
35,338
+2
+0% +$208 ﹤0.01% 2558
2025
Q1 		$3.13M Sell
35,336
-5,396
-13% -$526K ﹤0.01% 2781
2024
Q4 		$3.55M Sell
40,732
-25,925
-39% -$2.37M ﹤0.01% 2729
2024
Q3 		$6.17M Buy
66,657
+38,264
+135% +$3.8M ﹤0.01% 2203
2024
Q2 		$3.06M Buy
28,393
+2,441
+9% +$244K ﹤0.01% 2624
2024
Q1 		$2.46M Buy
25,952
+1,304
+5% +$112K ﹤0.01% 2812
2023
Q4 		$2.27M Sell
24,648
-28,270
-53% -$1.83M ﹤0.01% 2807
2023
Q3 		$2.66M Sell
52,918
-3,061
-5% -$164K ﹤0.01% 2580
2023
Q2 		$3.54M Buy
55,979
+10,821
+24% +$588K ﹤0.01% 2434
2023
Q1 		$2.03M Buy
45,158
+36,089
+398% +$1.63M ﹤0.01% 2843
2022
Q4 		$397K Sell
9,069
-479
-5% -$23K ﹤0.01% 3770
2022
Q3 		$629K Sell
9,548
-570
-6% -$36.6K ﹤0.01% 3547
2022
Q2 		$511K Sell
10,118
-31,751
-76% -$1.86M ﹤0.01% 3732
2022
Q1 		$2.67M Sell
41,869
-23,059
-36% -$1.66M ﹤0.01% 3018
2021
Q4 		$6.95M Sell
64,928
-18,248
-22% -$1.91M ﹤0.01% 2222
2021
Q3 		$8.55M Buy
83,176
+1,665
+2% +$155K ﹤0.01% 2350
2021
Q2 		$7.17M Sell
81,511
-11,044
-12% -$1.01M ﹤0.01% 2519
2021
Q1 		$9M Buy
92,555
+30,684
+50% +$3.06M ﹤0.01% 2292
2020
Q4 		$6.94M Buy
61,871
+17,769
+40% +$1.87M ﹤0.01% 2424
2020
Q3 		$4.09M Sell
44,102
-10,398
-19% -$801K ﹤0.01% 2696
2020
Q2 		$4.25M Buy
54,500
+9,545
+21% +$646K ﹤0.01% 2614
2020
Q1 		$2.63M Buy
44,955
+8,566
+24% +$551K ﹤0.01% 2769
2019
Q4 		$2.92M Sell
36,389
-5,645
-13% -$423K ﹤0.01% 3026
2019
Q3 		$3.09M Buy
42,034
+781
+2% +$67.5K ﹤0.01% 2964
2019
Q2 		$3.89M Buy
41,253
+7,160
+21% +$591K ﹤0.01% 2791
2019
Q1 		$2.73M Buy
34,093
+840
+3% +$62.1K ﹤0.01% 3091
2018
Q4 		$1.79M Buy
33,253
+535
+2% +$32.5K ﹤0.01% 3364
2018
Q3 		$2.55M Buy
32,718
+12,903
+65% +$897K ﹤0.01% 3211
2018
Q2 		$1.26M Sell
19,815
-5,107
-20% -$406K ﹤0.01% 3822
2018
Q1 		$2.29M Buy
24,922
+744
+3% +$64.1K ﹤0.01% 3269
2017
Q4 		$1.82M Sell
24,178
-17,460
-42% -$1.23M ﹤0.01% 3436
2017
Q3 		$2.9M Buy
41,638
+12,811
+44% +$685K ﹤0.01% 2990
2017
Q2 		$1.46M Buy
28,827
+6,899
+31% +$293K ﹤0.01% 3440
2017
Q1 		$877K Buy
21,928
+6,286
+40% +$225K ﹤0.01% 3840
2016
Q4 		$439K Buy
15,642
+8,800
+129% +$265K ﹤0.01% 4293
2016
Q3 		$203K Hold
6,842
– – ﹤0.01% 4478
2016
Q2 		$139K Buy
6,842
+2,880
+73% +$52.3K ﹤0.01% 4621
2016
Q1 		$71K Buy
3,962
+791
+25% +$13.7K ﹤0.01% 5067
2015
Q4 		$84K Sell
3,171
-14
-0.4% -$315 ﹤0.01% 5040
2015
Q3 		$68K Buy
3,185
+2,716
+579% +$75.1K ﹤0.01% 5132
2015
Q2 		$12K Buy
+469
New +$13.4K ﹤0.01% 5747

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wells Fargo's BPMC Position: Q3 2025 in Review

Wells Fargo sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 35,338 shares — an estimated $4.53M sold.

Wells Fargo first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $9M in Q1 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Wells Fargo reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Wells Fargo sold 35,338 Blueprint Medicines shares in Q3 2025, an estimated $4.53M.
  • Wells Fargo first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
  • Wells Fargo's Blueprint Medicines position peaked at $9M in Q1 2021.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.